Your browser is no longer supported. Please, upgrade your browser.
Settings
PFE Pfizer Inc. daily Stock Chart
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E23.68 EPS (ttm)1.24 Insider Own0.04% Shs Outstand6.17B Perf Week1.14%
Market Cap181.24B Forward P/E11.44 EPS next Y2.57 Insider Trans0.00% Shs Float6.17B Perf Month-2.35%
Income7.73B PEG4.36 EPS next Q0.55 Inst Own74.20% Short Float2.00% Perf Quarter-12.11%
Sales48.85B P/S3.71 EPS this Y-12.10% Inst Trans0.18% Short Ratio3.06 Perf Half Y-15.46%
Book/sh10.82 P/B2.71 EPS next Y10.56% ROA6.10% Target Price39.44 Perf Year-12.88%
Cash/sh3.35 P/C8.77 EPS next 5Y5.43% ROE14.90% 52W Range27.96 - 35.53 Perf YTD-8.13%
Dividend1.20 P/FCF- EPS past 5Y3.80% ROI8.40% 52W High-17.37% Beta0.90
Dividend %4.09% Quick Ratio1.30 Sales past 5Y-5.60% Gross Margin80.40% 52W Low5.00% ATR0.72
Employees78300 Current Ratio1.60 Sales Q/Q7.10% Oper. Margin29.00% RSI (14)41.42 Volatility2.11% 2.35%
OptionableYes Debt/Eq0.58 EPS Q/Q-50.00% Profit Margin20.70% Rel Volume0.81 Prev Close29.13
ShortableYes LT Debt/Eq0.44 EarningsFeb 02 BMO Payout68.30% Avg Volume40.26M Price29.36
Recom2.20 SMA20-1.69% SMA50-5.51% SMA200-9.93% Volume32,534,459 Change0.79%
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Apr-15-13Reiterated Barclays Equal Weight $25 → $32
Jan-30-13Reiterated UBS Buy $29 → $31
Jan-30-13Reiterated Argus Buy $28 → $32
Jan-22-13Reiterated Barclays Equal Weight $24 → $25
Nov-27-12Downgrade MKM Partners Buy → Neutral $29 → $25
Oct-05-12Reiterated MKM Partners Buy $27 → $29
Nov-01-11Downgrade Standpoint Research Buy → Hold
Oct-07-11Initiated MKM Partners Buy $20.50
Sep-14-11Downgrade Barclays Capital Overweight → Equal Weight $21 → $19
Feb-14-16 10:06AM  71% of Analysts See Pfizer as a Buy
10:05AM  Eli Lilly and Co.s Valuation Cheat Sheet for 4Q15
09:32AM  6 Biotech and Pharma Stocks Analysts Want You to Buy Now at 24/7 Wall St.
07:41AM  3 Under-Appreciated Healthcare Stocks I Still Love at Motley Fool
Feb-13-16 02:06PM  Alliance Datas Epsilon Segment Posted Stellar Results in 4Q15
09:20AM  3 Value Stocks Senior Citizens Could Buy Right Now at Motley Fool
Feb-12-16 08:15PM  Highlights from Billionaire Jim Simons Renaissance Technologies 13F: Apple, Pfizer & More at Insider Monkey
06:27PM  Loeb's Allergan Stake Grows by 50% at The Wall Street Journal
06:00PM  Regeneron Pharmaceuticals Major Revenue Sources in 4Q15
06:00PM  Bad News for Regeneron Pharmaceuticals for 4Q15 Revenue and Earnings
12:49PM  Don't bail on biotech: Pro
08:07AM  What Does Pfizers 2016 Guidance Look Like?
05:36AM  [$$] 3 Stock Picks From Only U.S. Fund That Rose in '08 at Barrons.com
04:26AM  [$$] GSK fined £37m for stifling launch of rival drug at Financial Times
Feb-11-16 02:06PM  Analyzing the Future Estimates for Eli Lilly and Co.
01:55PM  Kahn Brothers Top Stock Picks for Early 2016; Citigroup Inc. (C) Leading the Pack at Insider Monkey
11:16AM  [$$] J&J May See $4 Cash-Flow Cut From Remicade Copy at Barrons.com
09:32AM  Superbug review says more vaccines needed to reduce antibiotic use Reuters
Feb-10-16 04:19PM  Pfizer's Biosimilar of Remicade Recommended for Approval
01:55PM  Relypsa: This Biotech Just Released Stunning Data
01:16PM  Why Pfizer (PFE) Stock Is Rising Today at TheStreet
12:00PM  3 Value Stocks Ready to Outperform at TheStreet
09:51AM  Panel Recommends FDA Approval of Remicade Knockoff at The Wall Street Journal
09:15AM  Short Sellers Increase Bets in Major Pharma at 24/7 Wall St.
08:24AM  Early movers: TWX, DIS, DB, SPLS, CNX, P & more at CNBC
07:58AM  5 Safe, Strong Stocks to Add to Your Portfolio in Uncertain Times at TheStreet
07:00AM  AbbVie, Maker of World's No. 1 Drug, Bets on Synthetic Biology Startup at Forbes
01:05AM  Johnson & Johnsons Imbruvica Sees Increased Sales in 4Q15
12:53AM  Panel Recommends FDA Approval of Remicade Knockoff at The Wall Street Journal
12:01AM  Fidelity, Biogen, Sanofi Join $45M Bet on Alzheimer's and Parkinson's Startup at Forbes
Feb-09-16 06:57PM  Pfizer Commends The FDA Advisory Committees Vote To Approve Proposed Biosimilar Infliximab, The First Biosimilar Monoclonal Antibody Reviewed, For All Eligible Indications Business Wire
06:01PM  FDA panel backs lower-cost version of J&J's top-selling drug
05:10PM  Pfizer, Reynolds Among Recession Stock Plays GE, GM For Recovery
04:21PM  Pfizer Gets Back to Growth at Motley Fool
01:02PM  What Investors Can Expect from Healthcare Sector Companies
11:35AM  Why Merrill Lynch Sees Big Upside in Pfizer (and Even More With Allergan) at 24/7 Wall St.
10:58AM  Pfizers Loss of Product Exclusivity Affected Its 4Q15 Revenues
10:58AM  Pfizer Reported 7% Top Line Growth in 4Q15
10:20AM  Pfizer (PFE) Stock Rises, BofA/Merrill Lynch Names Top Pick at TheStreet
08:55AM  Top Analyst Upgrades and Downgrades: Apple, Freeport-McMoRan, Kinross Gold, Pfizer, Plains All American, Salesforce, Tesla, Yelp and More at 24/7 Wall St.
08:36AM  Alkermes CEO, Richard Pops, On ALKS 5461 And Challenges In Developing New Drugs For Depression at Forbes
08:33AM  [$$] Pfizer seeks to soothe fears over R&D at Financial Times
08:06AM  Eli Lilly and Co.s 4Q15: Profitability and Financial Guidance
07:55AM  1 Chart That's Bringing Big Smiles to America's Largest Companies at Motley Fool
Feb-08-16 05:26PM  Senator scrutinizes pharma links on government pain panel
01:42PM  Pfizer To Reorganize After Allergan Buyout, With Saunders President
10:44AM  The market in a minute: 5 stocks I really like at MarketWatch
10:26AM  Pfizer unveils management line up for combined company
10:22AM  [$$] Pfizer Outlines Post-Merger Management Slate at The Wall Street Journal
10:03AM  Pfizer Names New Executives to Run Units After Allergan Deal at Bloomberg
09:56AM  Pfizer to create operating unit after Allergan deal closes
09:30AM  Pfizer Names Executive Leadership Team for Combined Organization Upon Close of Proposed Allergan Transaction Business Wire
08:25AM  4 Big Dividend Pharmaceutical Stocks to Buy That Are Very Cheap Now at 24/7 Wall St.
05:53AM  Where is Ronald Reagan When You Need Him?
Feb-07-16 10:15AM  How Analysts View Pfizer and Merck After Earnings at 24/7 Wall St.
Feb-05-16 04:13PM  Call Martin Shkreli Whatever You Want, But Not A Pharma CEO at Forbes
01:19PM  A Checkup On A Big Healthcare ETF
09:43AM  Op-ed: On IEX, let the market decide at CNBC
09:31AM  US Service Sector Grew More Slowly in January
09:20AM  String of Q4 Earnings Beat Fails to Revive Pharma ETFs
07:00AM  Pfizer's Pipeline Productivity Is Improving at Morningstar
Feb-04-16 02:29PM  Its Time to Buy This Biotech Gem
10:45AM  Merrill Lynch Has 4 Very Oversold Blue Chip Dividend Stocks to Buy Now at 24/7 Wall St.
10:30AM  Pfizer Inc. Earnings Analysis: 2015 By the Numbers
08:25AM  Finding Value Inside Opportunity - Analyst Notes on Pfizer, Lowe's Companies, Starbucks and Boeing Accesswire
Feb-03-16 02:49PM  5 Stunning Numbers From Pfizer's Q4 Report That You May Have Missed at Motley Fool
02:00PM  Food incubator Brooklyn FoodWorks opens in former Pfizer plant at bizjournals.com
01:49PM  Global Manufacturing Activity Remained Subdued in January 2016
12:58PM  Here's Chardan's 'Conviction Sell' On Axovant
11:32AM  Eli Lilly and Co.s 4Q15 Earnings: An Overview
09:12AM  Merck gives cautious 2016 outlook as sales of top medicines lag
08:28AM  Biotech Stock Roundup: Biogen, Amgen Top Estimates; Zika Virus Grabs Attention
07:27AM  Pfizer, J&J, Merck evaluating technologies for Zika vaccine
Feb-02-16 07:07PM  Why Axovant Sciences Shares Are Crashing at Motley Fool
06:35PM  Gilead Q4 Earnings Beat Estimates; Guidance In Line With Street
05:45PM  Stocks End Sharply Lower as Oil Falls
04:35PM  ARIAD (ARIA) to Move AP32788 into Phase I/II Study in 2Q16
03:39PM  Health care analyst: How to play the current biotech market ahead of earnings
02:55PM  [$$] Pfizer Beats Expectations but Guidance Disappoints at The Wall Street Journal
02:41PM  Pfizer Looks Undervalued at Morningstar
02:26PM  [$$] Pfizer says US politicians will not scupper Allergan deal at Financial Times
02:20PM  Why Opko Health's Shares Fell 20% in January at Motley Fool
02:02PM  Pfizer Leads 3 Medical Stocks Moving On Earnings Beats
01:55PM  Pfizer's Move on Alzheimer's Drug Is Bad News for Axovant
01:48PM  Pfizer 2016 forecast disappoints
01:44PM  Pfizer earnings fall but tops Street 4Q forecasts
01:09PM  Axovant Falls Back to Earth at Bloomberg
01:08PM  Recession risks warn of severe drop in the stock market at MarketWatch
12:12PM  Top-Selling Prescription Drugs Have Seen Huge Price Hikes at Fortune
11:30AM  Stocks Follow Oil Lower
10:43AM  Pfizer Halts Drug Trial, Investors Flee Axovant at Forbes
10:17AM  Axovant Sinks on Pfizer Alzheimer's Drug Blowup at TheStreet
10:11AM  Pfizer Tops Earnings Estimates at Bloomberg
10:00AM  Pfizer Beats on Q4 Earnings, Revenues, Outlook Disappoints
09:33AM  Pfizer earnings top Wall Street estimates but outlook disappoints at USA TODAY
09:12AM  Pfizer (PFE) Stock Retreats in Pre-Market Trading on 2016 Guidance at TheStreet
08:53AM  PFIZER INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:45AM  Polcari: Will Weak Economy Force Fed To Go Negative On Rates?
08:20AM  Early movers: PFE, KORS, ADM, DOW, GOOG & more at CNBC
08:13AM  Pfizer (PFE) Tops on Q4 Earnings and Revenues
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, including inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women's/men's health. The VOC segment develops and commercializes vaccines, as well as products for oncology. It also provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control brand; respiratory products under the brand names of Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and personal care products under the ChapStick and Preparation H brands. The GEP segment offers patent-protected products that have lost marketing exclusivity in various markets; and generic pharmaceuticals, and sterile injectable and biosimilar development products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has strategic collaboration with KineMed Inc.; collaborations with BIND Therapeutics, Inc., Merck KGaA, and Syndax Pharmaceuticals, Inc.; research collaboration with Schrdinger, Inc.; license and collaboration agreement with Servier; strategic drug discovery agreement with Heptares; and collaboration agreement with Portola Pharmaceuticals Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BOURLA ALBERTGroup PresidentDec 15Option Exercise26.2030,000786,000140,560Dec 16 06:46 PM
YOUNG JOHN DGroup PresidentDec 14Option Exercise26.2031,500825,300163,999Dec 16 06:55 PM
PFIZER INC10% OwnerOct 06Buy7.00714,2854,999,9952,253,509Oct 07 05:42 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerJul 30Sale35.6524,704880,646174,611Aug 03 07:24 AM
OLSON LAURIE JExecutive Vice PresidentJun 11Option Exercise25.8726,000672,62096,113Jun 12 09:26 AM
OLSON LAURIE JExecutive Vice PresidentJun 11Sale34.3926,000894,15570,113Jun 12 09:26 AM
HILL CHARLES HExecutive Vice PresidentMay 29Sale34.9242,8701,497,02069,357Jun 02 04:54 PM
SUSMAN SALLYExecutive Vice PresidentMar 12Sale34.0046,1791,570,086150,899Mar 13 10:39 AM
Dolsten MikaelPresident R&DMar 05Sale34.4658,2982,009,152355,911Mar 06 07:32 PM
READ IAN CChairman & CEOMar 05Sale34.6267,5002,336,7931,408,457Mar 06 07:19 PM
OLSON LAURIE JExecutive Vice PresidentFeb 25Option Exercise17.6921,115373,52481,240Feb 27 06:49 PM
HILL CHARLES HExecutive Vice PresidentFeb 25Option Exercise17.6922,523398,432121,572Feb 27 06:42 PM
JOHNSON RADY AExecutive Vice PresidentFeb 25Option Exercise17.6919,426343,64656,250Feb 27 06:42 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 25Option Exercise17.6932,855581,205141,441Feb 27 06:42 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 25Option Exercise17.69101,3511,792,899227,982Feb 27 06:42 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 25Option Exercise17.6923,649418,35188,933Feb 27 06:42 PM
READ IAN CChairman & CEOFeb 25Option Exercise17.69197,0723,486,2041,568,718Feb 27 06:50 PM
SUSMAN SALLYExecutive Vice PresidentFeb 25Option Exercise17.6995,7211,693,304261,233Feb 27 06:56 PM
YOUNG JOHN DGroup PresidentFeb 25Option Exercise17.6949,364873,249159,673Feb 27 06:56 PM